Article Sidebar

PDF
Date Published: 18/07/2023
Abstract Views: 135
Views PDF: 111
DOI: https://doi.org/10.51298/vmj.v528i1.5990
Issue
Vol. 528 No. 1 (2023)
Section
Các bài báo
How to Cite
Nguyễn, N. H., Bùi, H. N. K., Nguyễn, Đắc N. T., & Nguyễn, N. K. (2023). PATTERN OF DRUG USE IN THE TREATMENT OF COLON CANCER AT THONG NHAT HOSPITAL IN HO CHI MINH CITY. Vietnam Medical Journal, 528(1). https://doi.org/10.51298/vmj.v528i1.5990

PATTERN OF DRUG USE IN THE TREATMENT OF COLON CANCER AT THONG NHAT HOSPITAL IN HO CHI MINH CITY

Như Hồ Nguyễn1,, Hoàng Ngọc Khánh Bùi1, Đắc Nhân Tâm Nguyễn2, Ngọc Khôi Nguyễn1
1 University of Medicine and Pharmacy at Ho Chi Minh City
2 Ho Chi Minh City Thong Nhat Hospital

Main Article Content

Abstract

Objectives: To investigate pattern of drug use for the treatment of colon cancer in patients with newly indicated chemotherapy and treatment response after 12 months of follow-up. Patients and methods: A retrospective study was conducted on patients aged 18 and over, diagnosed with colon cancer and indicated at least one drug for treatment of colon cancer during 01/01/2019-01/01/2021, with no history of chemotherapy use. Results: A total of 88 patients with 736 treatment sessions were included. Average age was 63.5±13.7; 72,7% were men. Patients with stage 3 disease accounted for 55.7%. XELOX regimen was the most commonly indicated (96.6%); the only targeted drug was bevacizumab (14.1%). Average overall survival was 11.3±0.2 months. Conclusion: Most patients were in the advanced stage of colon cancer and treated with XELOX regimen. The study have shown the overal survival period after 12 months of drug treatment

Article Details

Keywords

Colon cancer, chemotherpay, targeted therapy, XELOX

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi: https://doi.org/10.3322/caac.21660
2. Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):22. doi:10.1038/s41392-020-0116-z
3. Lauby-Secretan B, Vilahur N, Straif K. IARC Handbook of Cancer Prevention Vol. 17 - Colorectal Cancer Screening. Vol 17. International Agency for Research Cancer; 2019. doi:10.1200/jgo.18.17700
4. Hu JM, Wu JJ, Hsu CH, et al. Association between gastroesophageal reflux disease and colorectal cancer risk: a population-based cohort study. Int J Colorectal Dis. 2021;36(11):2411-2418. doi:10.1007/S00384-021-03873-2
5. Hugen N, van de Velde CJH, de Wilt JHW, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(3):651-657. doi:10.1093/annonc/mdt591
6. Benson AB, Al-Hawary MM, Azad N, et al. NCCN Guidelines Version 1.2022 Colon Cancer Continue NCCN Guidelines Panel Disclosures. 2022.
7. Cassidy J, Clarke S, Díaz-Rubio E, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer. 2011;105(1):58. doi:10.1038/BJC.2011.201
8. Cancer survival by stage at diagnosis for England, 2019. Office for National Statistics. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancersurvivalinengland/stageatdiagnosisandchildhoodpatientsfollowedupto2018#international-comparisons Accessed Mar 29 2023.